{"nctId":"NCT01939314","briefTitle":"Sphenopalatine Nerve Block for Headache Tx360","startDateStruct":{"date":"2012-10"},"conditions":["Headache","Migraine"],"count":93,"armGroups":[{"label":"Bupivacaine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Bupivacaine"]},{"label":"Normal Saline","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Bupivacaine","otherNames":[]},{"name":"Placebo","otherNames":["Normal Saline"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* are 18 - 65 years of age\n* present to emergency department (ED) triage with chief complaint of crescendo-onset anterior/frontal headache (affecting frontal, temporal, orbital, maxillary, and mandible region)\n* have a normal neurological exams\n\nExclusion Criteria:\n\n* are less than 18 years old or greater than 65\n* have any focal neurological dysfunction signs or symptoms\n* have a posterior/occipital/cervicogenic source predominance of headache\n* are febrile (oral temperature 37.7 C or 100 F) or signs of acute or chronic sinusitis, such as congestion, has been present more than 10 days, there is a high fever, the nasal mucus is an abnormal color, or complains of face pain or headaches\n* have self treated with pain medication or anti-emetic 4 hours prior to arrival\n* have a history of peripheral vascular disease, cancer, or HIV infection\n* are known to be pregnant","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Who Reported a 50% or Greater Reduction in Pain at 15 Minutes as Measured on the 100mm Visual Analog Scale","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.8","spread":null},{"groupId":"OG001","value":"41.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Categorical Pain Relief","description":"Categorical Pain Relief at 15 minutes. Participants were asked to categorize their pain relief at 15 minutes as \"No\", \"Little\", \"Some\", \"A Lot\" or \"Complete\". The table displays the number of participants who identified their pain relief in the categories provided.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Headache Free at 24 Hours","description":"The percentage of patients that were headache free at 24 hours by follow-up phone conversation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.2","spread":null},{"groupId":"OG001","value":"47.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":41},"commonTop":["Nasal Congestion","Minor Epistaxis","Sore Throat","Hoarseness","Nasal Dryness"]}}}